Genentech and Novartis have teamed up with Food Allergy Research & Education (FARE) to enhance the safety of children with ...

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Telix is in a strong financial position with net cash of AUD 140 million as of December 2024. We forecast free cash flow averaging 87% of net income over the next 10 years, and in the absence of major ...

Novartis is one of the world's top pharmaceutical ... Three years later, the company has a commercial presence in Germany, France, England, Italy, Russia and the US. By 1884, Bindschedler ...

New board reflects company's added focus on oncology & autoimmune diseases; SARASOTA, Fla. and MIAMI, Feb. 19, 2025 (GLOBE ...

Peter Shadday becomes CEO as company is moving into a commercial-stage company, increasingly focused on U.S. market opportunities Dr. Sabine Häussermann transitions to newly created role of Chief ...

The decision comes in the wake of changes to Novartis' organisational structure ... a single unit with separate US and international commercial operations, and a cost-cutting drive that aims ...

This week, the European Commission granted approval to Merck’s MRK novel HIF-2α inhibitor, Welireg, for two indications. The ...

Ionis Pharmaceuticals IONS incurred a loss of 66 cents per share for fourth-quarter 2024, which was narrower than the Zacks ...